We have previously shown that low extracellular pH (pHe) promotes cell killing by the tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL). In this study, we examined whether amiloride, an inhibitor of the Na þ / H þ antiporter capable of lowering the intracellular pH (pHi), can potentiate TRAIL-induced apoptotic death. Human prostate adenocarcinoma DU-145 cells were treated with various concentrations of TRAIL (10-200 ng/ml) and/or amiloride (0.1-1 mM) for 4 h. Amiloride, which caused little or no cytotoxicity by itself, enhanced TRAIL-induced apoptosis. The TRAILmediated activation of caspase, and PARP (poly (ADPribose) polymerase) cleavage were both promoted by amiloride. Western blot analysis showed that combined treatment with TRAIL and amiloride did not change the levels of TRAIL receptors (death receptor (DR)4, DR5, and DcR2 (decoy recepter 2) or antiapoptotic proteins (FLICE-inhibitory protein (FLIP), inhibitor of apoptosis (IAP), and Bcl-2). However, unlike pHe, amiloride promoted the dephosphorylation of Akt. Interestingly, amiloride also induced the dephosphorylation of P13K (phosphatidylinositol 3-kinase) and PDK-1 (phosphoinositide-dependent kinase-1) kinases along with PTEN (phosphatase and tensin homolog deleted on chromosome 10) and PP1a phosphatases. In vitro kinase assays revealed that amiloride inhibited phosphorylation of kinases and phosphatases by competing with ATP. Taken together, the present studies suggest that amiloride enhances TRAIL-induced cytotoxicity by inhibiting phosphorylation of the PI3K-Akt pathway-associated kinases and phosphatases.
Introduction
The abnormalities of the tumor vasculature, that is, a loss of the natural hierarchy of blood vessels, changes in the vascular density, and loss of the physiological regulation of blood perfusion, have been well documented (Endrich et al., 1982) . These abnormalities cause an insufficient blood supply and development of a pathophysiological tumor microenvironment including low extracellular pH (pHe) (Wike-Hooley et al., 1984) . Recently, we demonstrated that low pHe augments apoptosis induction by TRAIL (tumor necrosis factorrelated apoptosis-inducing ligand), a potent anticancer agent (Lee et al., 2004) . The effect of a low pH is probably due to cytosol acidification and loss of the H þ gradient normally presents across the inner membrane of mitochondria during apoptosis. TRAIL-induced association of truncated Bid with Bax and cytochrome c release are facilitated at low pH (Lee et al., 2004) .
In this study, we investigated whether amiloride (3,5 diamino-6-chloro-N-(diaminomethylene) pyrazinecarboximide), an inhibitor of the Na þ /H þ antiporter, can promote TRAIL-induced apoptotic death. It is well known that mammalian cells possess effective intracellular pH (pHi) regulatory mechanisms, such as the Na þ / H þ antiporter and HCO 3 À /Cl À exchange, through which the intracellular environment is maintained at a near neutral pH even in an acidic extracellular environment (Frelin et al., 1988) . We postulate that acidification of the pHi by blocking the Na þ /H þ antiporter enhances TRAIL cytotoxicity.
TRAIL/APO-2L is a type II integral membrane protein belonging to the tumor necrosis factor (TNF) family. TRAIL is a 281-amino-acid protein, related most closely to Fas/APO-1 ligand. Like Fas ligand (FasL) and TNF, the C-terminal extracellular region of TRAIL (amino acids 114-281) exhibits a homotrimeric subunit structure (Pitti et al., 1996) . TRAIL binds to the death receptors such as TRAIL-R1 (DR4, death recepter 4) and TRAIL-R2 (DR5, death receptor 5), and induces the apoptotic signal. Both DR4 and DR5 contain a cytoplasmic death domain that is required for TRAIL receptor-induced apoptosis. TRAIL also binds to TRAIL-R3 (DcR1, decoy recepter 1) and TRAIL-R4 (DcR2, decoy recepter 2), which act as decoy receptors by inhibiting TRAIL signaling (Degli-Esposti et al., 1997a, b; Marsters et al., 1997; Pan et al., 1997a, b; Sheridan et al., 1997; Walczak et al., 1997) . Unlike DR4 and DR5, DcR1 does not have a cytoplasmic domain, while DcR2 retains a cytoplasmic fragment containing a truncated form of the consensus death domain motif (Pan et al., 1997a, b) . The relative resistance of normal cells to the apoptotic-inducing effects of TRAIL has been explained by the presence of large numbers of the decoy receptors on normal cells (Gura, 1997; Ashkenazi and Dixit, 1999) .
Recently, this hypothesis has been challenged based on the results showing poor correlations between DR4, DR5, and DcR1 expression and sensitivity to TRAILinduced apoptosis in normal and cancerous breast cell line (Keane et al., 1999) and melanoma cell lines (Griffith et al., 1998) . This discrepancy indicates that other factors such as death inhibitors including FLICE (Fas-associated death domain-like interleukin-1b-converting enzyme)-inhibitory protein (FLIP) (Griffith et al., 1998) , Fas-associated protein (FAP-1) (Sato et al., 1995) , Bcl-2 (Wen et al., 2000) , Bcl-X L (Wen et al., 2000) , Bruton's tyrosine kinase (BTK) (Vassilev et al., 1999) , silencer of death domain (SODD) (Tschopp et al., 1999) , toso (Hitoshi et al.,1998) , inhibitor of apoptosis (IAP) (Kothny-Wilkes et al., 1999), X-linked inhibitor of apoptosis (XIAP) (Deveraux and Reed, 1999) , and survivin (Tamm et al., 1998) may be responsible for the differential apoptotic effect of TRAIL. Previous studies show that chemotherapeutic agents (Griffith et al., 1998; Keane et al., 1999; Nagane et al., 2000) and ionizing radiation (Chinnaiyan et al., 2000) can increase TRAIL-induced cytotoxicity by decreasing intracellular levels of FLIP (Griffith et al., 1998) or increasing DR5 gene expression (Sheikh et al., 1998; Chinnaiyan et al., 2000; Nagane et al., 2000) . We hypothesize that amiloride promotes TRAIL-induced apoptotic death by modulating the levels of TRAIL receptors and antiapoptotic molecules.
In addition to alterations of the levels of TRAIL receptors and antiapoptotic molecules, post-translational modification of antiapoptotic molecules such as phosphorylation of Akt may contribute to amiloride's potentiation of TRAIL-induced apoptosis. Akt (also known as PKB) is a serine/threonine kinase. It was originally identified as the cellular counterpart of the v-Akt transforming protein of a retrovirus (AKT8) that caused T-cell lymphomas in mice (Staal, 1987) . Akt is recruited to the plasma membrane and activated by phosphorylation at threonine 308 and serine 473 in response to growth factors (Alessi et al., 1996) . The molecule responsible for the recruitment of Akt is phosphatidylinositol (PI) 3-kinase (PI3K) (Alessi et al., 1996; Andjelkovic et al., 1997) . PI3K consists of a regulatory subunit (p85) that binds to an activated growth factor/cytokine receptor and undergoes phosphorylation, activating its catalytic subunit (P110) (Rodriguez-Viciana et al., 1996) . PI3K phosphorylates phosphoinositides at the 3 0 -position of the inositol ring, and its major lipid product is phosphatidylinositol 3,4,5-triphosphate (PIP 3 ) (Rameh and Cantley, 1999) . PIP 3 facilitates the recruitment of Akt to the plasma membrane through binding with the pleckstrin homology (PH) domain of Akt (Rameh and Cantley, 1999) . At the plasma membrane, Akt is activated by phosphoinositide-dependent kinase-1 (PDK-1) through phosphorylation at threonine 308 and serine 473 (Anderson et al., 1998; Andjelkovic et al., 1997) . Activated Akt phosphorylates several transcription factors (e.g. NF-kB, Forkhead, CREB) (Du and Montminy, 1998; Romashkova and Makarov, 1999; Kashii et al., 2000) as well as proapoptotic molecules such as Bad and procaspase-9. Phosphorylation of Bad and procaspase-9 results in inactivation of these molecules and inhibits apoptosis (Datta et al., 1997; Kennedy et al., 1997; Cardone et al., 1998) . In this study, we observed that amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of Akt rather than by decreasing the levels of TRAIL receptors or antiapoptotic molecules.
Results

Amiloride enhances TRAIL-induced cytotoxicity
To investigate the effect of amiloride on TRAILinduced cytotoxicity, human prostatic adenocarcinoma DU-145 cells were treated with TRAIL in the presence of absence of amiloride. Figure 1a and b show that little or no cytotoxicity was observed with amiloride (0.1-1 mM) alone. In contrast, TRAIL-induced cytotoxicity was concentration-dependent, and was significantly increased in the presence of 1 mM amiloride (Figure 1b) . For example, when cells were treated for 4 h with 200 ng/ml TRAIL in the presence or absence of 1 mM amiloride, the surviving fraction was 17 or 43%, respectively. Similar results were observed by DAPI (4 0 ,6-diamidino-2-phenylindole) staining ( Figure 1c ). DAPI staining of cells treated with TRAIL in combination with amiloride showed the presence of many cells with condensed nuclei, a morphological change that is associated with apoptosis. Apoptotic death was also evaluated by flow cytometric analysis in combination with 7-amino-actinomycin-D (7-ADD) and annexin V staining assays (Figure 1d ). Figure 1d clearly shows that amiloride promoted TRAIL-induced apoptotic death (annexin V þ /7-AADÀ).
Effect of amiloride on TRAIL-induced apoptosis
Additional studies were designed to examine whether the combination of amiloride and TRAIL treatment of DU-145 cells enhances poly (ADP-ribose) polymerase (PARP) cleavage, the hallmark feature of apoptosis. PARP (116 kDa) was cleaved yielding a characteristic 85 kDa fragment in the presence of TRAIL (Figure 2 ). This cleavage was enhanced by treatment with amiloride ( Figure 2 ). For example, data from densitometer analysis show that amiloride promoted a 3.6-fold increase in the 85 kDa fragment when treatment of cells with 10 ng/ml TRAIL in combination with amiloride was compared with TRAIL alone. The cleavage of PARP was not observed by treatment with amiloride alone (data not shown). We extended our studies to investigate whether amiloride enhances TRAIL-induced cytotoxicity by increasing the activation of caspase. Figure 2 demonstrates that amiloride promoted TRAILinduced caspase-8 activation. Western blot analysis shows that procaspase-8 (54/55 kDa) was cleaved to the intermediates (41 and 43 kDa) and active form (18 kDa) in the presence of TRAIL. The cleavage of procaspase-8 was promoted by treatment with amiloride. The combined treatment of TRAIL and amiloride also resulted in an increase in caspase-9 activation (Figure 2 ). TRAIL induced proteolytic processing of procaspase-9 (48 kDa) into its active form (37 kDa). The activation of caspase-9 induced by TRAIL was enhanced by amiloride (Figure 2 ). Amiloride also increased TRAIL-induced caspase-3 activation (Figure 2 ). Western blot analysis shows that procaspase-3 (32 kDa), the precursor form of caspase-3, was cleaved to active form (17 kDa) in the presence of TRAIL. The combined treatment with amiloride and TRAIL increased the level of the active form. Amiloride alone did not activate caspases (data not shown). We further examined whether amiloride affects apoptosis by a stimulus other than TRAIL. Like TRAIL, FasL induced PARP cleavage, the hallmark feature of apoptosis (Figure 3a) . This cleavage was promoted by treatment with amiloride (lane 3 versus lane 5 in Figure 3a) . We also examined 
Effects of amiloride on the level of TRAIL receptor family and antiapoptotic proteins
Previous studies demonstrate that increased DR5 levels induced by genotoxic agents (Sheikh et al., 1998; Chinnaiyan et al., 2000; Nagane et al., 2000) or decreased FLIP expression induced by glucose deprivation (Nam et al., 2002) is responsible for increasing TRAIL cytotoxicity. Thus, we examined whether changes in the amounts of TRAIL receptors and antiapoptotic proteins are associated with the promotion of apoptosis by TRAIL in combination with amiloride. DU-145 cells were treated with 200 ng/ml TRAIL in the presence of 1 mM amiloride. Data from Western blot analysis reveal that the combined treatment did not significantly alter the levels of DR4, DR5, DcR2, FLIP L , FLIP S , IAP-1, IAP-2, Bcl-X L , and Bcl-2 ( Figure 4 ). Amiloride alone also did not change the levels of TRAIL receptors and antiapoptotic proteins (data not shown).
Effect of amiloride on Akt phosphorylation
It is well known that elevated Akt activity protects cells from TRAIL-induced apoptosis (Nesterov et al., 2001) . We postulated that amiloride inhibits Akt activity and consequently enhances TRAIL-induced cytotoxicity. To examine whether amiloride inhibits Akt activity by dephosphorylating Akt, DU-145 cells were treated with 1 mM amiloride for various periods (5-60 min) and the level of phosphorylated Akt was measured. Figure 5a shows that Akt was rapidly dephosphorylated within 5 min of amiloride addition without changing the Akt protein level. Data from densitometer analysis show a 16.3-fold decrease in the level of phosphorylated Akt during treatment with amiloride. TRAIL treatment did not alter amiloride-induced dephosphorylation of Akt ( Figure 5b ). Since several researchers have demonstrated that overexpression of Na þ /H þ exchanger promotes cell survival and Akt activity (Barriere et al., 2001; Wu et al., 2004) , we investigated whether another ion transport inhibitor such as DIDS (4,4 0 -diisothiocyanatostilbene-2,2 0 -disulfonic acid) dephosphorylates Akt. Figure 5c shows that Akt was also dephosphorylatd by treatment with 200 mM DIDS. These results suggest that promoting intracellular acidification inhibits Akt activity by dephosphorylation. Thus, we further investigated whether pHe also dephosphorylates Akt. Figure 5d reveals that pHe did not alter the level of phosphorylated Akt. These results suggests that the mechanism of pHe-enhanced TRAIL cytotoxicity (Lee et al., 2004) is not the same as that of amiloride-promoted TRAIL apoptotic death.
To examine whether dephosphorylation of Akt during amiloride treatment is mediated through activation of phosphatase, we treated DU-145 cells with okadaic acid, a serine phosphatase inhibitor. Figure 6a shows that amiloride-induced Akt dephosphorylation was suppressed by pretreatment with 1 mM, but not by 0.1 mM, okadaic acid. For example, data from densitometer analysis show that the level of phosphorylated Akt was reduced by 94% during treatment with amiloride. However, the phosphorylated Akt level decreased only 13% in the 1 mM okadiac acid-pretreated cells. It is well known that okadaic acid inhibits both protein phosphatase 2A (PP2A) and protein phosphatase 1 (PP1) both serine/threonine phosphatases, at higher concentrations (IC 50 ¼ 150 nM), but it inhibits only PP2A at low concentrations (IC 50 o0.1 nM). These results suggest that PP1 rather than PP2A plays an important role in the regulation of Akt phosphorylation, since recent studies have demonstrated that dephosphorylation of Akt is regulated by PP1 (Xu et al., 2003) . Unlike okadaic acid, sodium orthovanadate (Na 3 VO 4 ), an inhibitor of tyrosin phosphatases, and emodin, a tyrosine kinase inhibitor, did not prevent dephosphorylation of Akt during treatment with amiloride (Figure 6b and c) . As a next step, we repeated the procedure to examine a possible involvement of PP1 in the amiloride-induced dephosphorylation of Akt. Figure 7a shows that amiloride induced dephosphorylation (activated) of PP1 and 1 mM okadaic acid substantially prevented dephosphorylation of PP1. Amiloridepromoted TRAIL-induced PARP cleavage was also significantly inhibited by treatment with 1 mM okadaic acid (Figure 7b ). Previous studies demonstrated that Akt activation is regulated through the PI3K-Akt pathway. We further examined whether amiloride specifically activates PP1 activity or nonspecifically affects the PI3K-Akt pathway-associated kinases and phosphatases. Figure 8a shows that amiloride induced dephosphorylation of not only PP1 but also PTEN (phosphatase and tensin homolog deleted on chromosome 10), which is known to be a major negative regulator of the PI3K-Akt signaling pathway. Amiloride also induced dephosphorylation of the PI3K-Akt pathway-associated kinases such as PI3K and PDK-1 (Figure 8b ). We further examined whether amiloride had an affect on phosphorylation of a substrate that is not in the PI3K/PDK-1/ Akt signaling pathway. Figure 8c shows that hydrogen peroxide activated JNK (phosphorylation of JNK1 and JNK2) and its phosphorylation was not inhibited by treatment with amiloride. The effect of amiloride on Akt was compared with LY294002 and wortmannin, inhibitors of PI3K. Figure 9a shows that all these drugs induced dephosphorylation of Akt. However, unlike amiloride, LY294002 and wortmannin did not induce dephosphorylation of PI3K, PDK-1 and PTEN. Nevertheless, LY294002 and wortmannin promoted TRAIL-induced cytotoxicity (Figure 9b ). These results indicate that Akt inactivation (dephosphorylation) is responsible for the amiloride-induced enhancement of TRAIL cytotoxicity.
Mechanism of amiloride-induced alterations of phosphatase and kinase activities
Davis and Czech (1985) reported that amiloride acts as an ATP analog that causes the formation of nonproductive enzyme-substrate complexes. We hypothesized that amiloride competes with ATP, thereby inhibiting protein posphorylation. To test this hypothesis, as a first step we investigated whether amiloride directly dephosphorylates an active Akt. Figure 10 shows that amiloride did not directly dephosphorlylate Akt when mixed with phosphorylated Akt (lane 2 in Figure 10 ). In addition, amiloride did not inhibit dephosphorylation of Akt by PP1 (lane 5 in Figure 10 ). As a next step, we examined whether amiloride blocks the kinase-mediated phosphorylaton process. Figure 11a shows that unphosphorylated Akt was phosphorylated by active PDK-1 in vitro. Amiloride, but not dimethylsulfoxide (DMSO), inhibited phosphorylation of Akt (Figure 11b) . Data from densitometer analysis show that phosphorylation Figure 12 . Casein kinase II (CK2), a protein kinase for PTEN, phosphorylated PTEN in vitro and its phosphorylation was blocked by amiloride in a dose-dependent manner (Figure 12a ). Figure 12b shows that amiloride blocks the kinase-mediated phosphorylaton process by competing with ATP.
Discussion
Amiloride is known to inhibit tyrosine kinase activity of growth factor receptors (Davis and Czech, 1985) , Na þ / Ca 2 þ exchange (Smith et al., 1982) , (Na Soltoff and Mandel, 1983) , and serine kinase activity (Ralph et al., 1982) . The data presented in this report demonstrate that amiloride is a potent promoter of TRAIL-induced apoptotic death (Figures 1 and 2) . This is probably due to the amiloride-induced dephosphorylation (inactivation) of Akt, an antiapoptotic protein.
Our studies also reveal that amiloride causes a decrease (Figure 8 ). The inhibition of kinases by amiloride can be relieved at high ATP concentrations which indicates that the inhibition of kinase activity is competitive with ATP ( Figure 12b ; Holland et al., 1983) . Thus, amiloride may act as an ATP analog and directly inhibit kinase activity by decreasing protein phosphorylation (Davis and Czech, 1985) . Indeed, our results from in vitro kinase assays show that amiloride directly inhibits PDK-1 and CK2 kinase activity (Figures 11 and 12) .
It has previously been suggested that a possible mechanism of biochemical action of amiloride is the inhibition of kinase activity (Davis and Czech, 1985; Ralph et al., 1982) . In addition to the inhibition of kinase activity, our data indicate that amiloride activates PTEN and PP1 phosphatases. PTEN protein is composed of an N-terminal dual specificity phosphatase-like enzyme domain, and a C-terminal regulatory domain that binds to phospholipid membranes. It exhibits phosphatase activity towards both protein substrates and the lipid second messenger, PIP3 (Maehama and Dixon, 1998; Myers et al., 1997) . PTEN reverses the action of PI3K by catalyzing the removal of the 3 0 phosphate of PIP3. PTEN is phosphorylated by protein kinase CK2 (Torres and Pulido, 2001 ) in a constitutive manner at a cluster of Ser/Thr residues located in the C-terminal tail region. The C-terminal tail region also contains the PSD-95/Dlg/ZO-1 homology (PDZ) domain-binding sequence. Recent studies reveal that phosphorylation of the C-terminal tail targets PTEN to the plasma membrane, not by blocking the PDZ domain-binding site but by interfering with the electrostatic membrane binding of PTEN (Das et al., 2003) . In this study, we observed that PTEN was dephosphorylated (activated) by treatment with amiloride (Figure 8a) , causing it to bind to the plasma membrane. This suggests that the plasma membrane bound PTEN mediates the amiloride-induced dephosphorylation (inactivation) of Akt by inhibiting recruitment of Akt to the plasma membrane and consequently enhancing TRAIL cytotoxicity (Kandasamy and Srivastava, 2002) . Previous studies showed that Akt activity was also regulated by Ser/Thr phosphatases such as PP2A (Resjo et al., 2002) or PP1 (Xu et al., 2003) . However, pharmacokinetics studies reveal that PP1 rather than PP2A is responsible for regulation of Akt phosphorylation (Xu et al., 2003) . It is well known that the activity of PP1 is regulated by phosphorylation of its catalytic subunit. Upon phosphorylaton of Thr 320 , the COOH terminus of PP1 folds back to mask its catalytic center (Goldberg et al., 1995) . Our data clearly demonstrate that amiloride dephosphorylates (activates) PP1 (Figure 7 ) as well as Akt (Figures 5 and 6) . The amiloride-mediated dephosphorylation of PP1 and Akt is inhibited by 1 mM, but not by 0.1 mM of okadaic acid (Figure 7) . Previous pharmacokinetics studies demonstrate that okadaic acid inhibits only PP2A at low concentrations (IC 50 o0.1 nM), but both PP1 and PP2A at higher concentrations (IC 50 ¼ 150 nM). Taken together, our results are consistent with previous observations that PP1 rather than PP2A regulates Akt phosphorylation (Xu et al., 2003) .
Previous studies have shown that constitutively active Akt blocks TRAIL cytotoxicity Thakkar et al., 2001) . Downregulation of Akt activity of PI3K inhibitors, wortmannin and LY294002, promotes TRAIL cytotoxicity (Figure 9 Effect of amiloride on PDK-1 kinase activity. DU-145 cells were transfected with pcDNA3myc-PDK-1. At 1 day after transfection, myc-PDK-1 was immunoprecipitated with anti-myc antibody. For in vitro PDK-1 kinase assays, the immune complex was incubated with purified inactive Akt protein in the presence or absence of amiloride. The sample was separated by SDS-PAGE and immunoblotted with anti-phospho-Akt, anti-PDK-1 antibody Martelli et al., 2003) . This is probably due to inhibiting Akt-mediated antiapoptotic effects. A number of proapoptotic proteins have been identified as direct Akt substrates, including BAD, caspasase-9, and Forkhead transcription factors (Cross et al., 1995; Datta et al., 1997; del Peso et al., 1997; Cardone et al., 1998; Brunet et al., 1999; Hetman et al., 2000) . The proapoptotic function of these molecules is suppressed upon phosphorylation by Akt. Akt also induces the degradation of IkB by promoting IKKa activity and subsequently stimulating the nuclear translocation of NF-kB (Ozes et al., 1999) . Recently, we (Nam et al., 2002) and Panka et al. (2001) reported that the PI3K-Akt-NF-kB pathway may regulate the expression of FLICE-inhibitory protein (FLIP), an antiapoptotic molecule. We postulate that amiloride-mediated dephosphorylation of Akt leads to activation of proapoptotic molecules and results in enhancement of TRAILinduced apoptotic death. Overall, our model may provide important insights into how amiloride promotes TRAIL-induced apoptotic death. We believe that this model provides a framework for future studies.
Materials and methods
Cell culture and survival assay
Human prostate adenocarcinoma DU-145 cell line and human normal prostate epithelial PZ-HPV-7 cell line were obtained from the American Type Culture Collection (Manassas, VA, USA). DU-145 cells were cultured in DMEM medium (Gibco BRL, Gaithersburg, MD, USA) containing 10% fetal bovine serum (HyClone, Logan, Utah, USA) and 26 mM sodium bicarbonate for monolayer cell culture. PZ-HPV-7 cells were cultured in keratinocyte serum-free medium (K-SFM, Gibco BRL) containing 10% fetal bovine serum, L-glutamine, human recombinant epidermal growth factor (5 ng/ml), and bovine pituitary extract (50 mg/ml). The dishes containing cells were kept in a 371C humidified incubator with a mixture of 95% air and 5% CO 2 . At 1 day prior to the experiment, cells were plated into 60-mm dishes. For trypan blue exclusion assay (Burow et al., 1998) , trypsinized cells were pelleted and resuspended in 0.2 ml of medium, 0.5 ml of 0.4% trypan blue solution, and 0.3 ml of phosphate-buffered saline solution (PBS). The samples were mixed thoroughly, incubated at room temperature for 15 min and examined under a light microscope. At least 300 cells were counted for each survival determination.
Drug treatment
Wortmanin, sodium orthovanadate, hydrogen peroxide, 4,4 0 -diisothiocyanatostilbene-2,2 0 -disulfonic acid (DIDS), and 3,5-diamino-6-chloro-N-(diaminomethylene)pyrazinecarboximide (amiloride) were obtained from Sigma Chemical Co. (St Louis, MO, USA). LY294002 was purchased from Cell Signaling (Beverly, MA, USA), and okadaic acid from Calbiochem (San Diego, CA, USA). A stock solution was prepared in DMSO.
Production of recombinant TRAIL
A human TRAIL cDNA fragment (amino acids 114-281) obtained by RT-PCR was cloned into a pET-23d (Novagen, Madison, WI, USA) plasmid, and His-tagged TRAIL protein was purified using the Qiagen express protein purification system (Qiagen, Valencia, CA, USA).
Morphological evaluation
Morphological changes in the nuclear chromatin in cells undergoing apoptosis were detected by staining with the DNA binding fluorochrome 4 0 ,6-diamidino-2-phenylindole (DAPI). Cells were grown on glass coverslips at a density of 2 Â 10 5 cells/well. Cells treated with TRAIL, amiloride, or TRAIL in combination with amiloride for 4 h. Cells were washed twice with PBS and fixed by incubation in 70% ethanol for 30 min. Following washes with PBS, cells were incubated in 1 mg/ml DAPI solution for 30 min in the dark. Coverslips were then washed with PBS and analysed by fluorescence microscopy. 
Flow cytometry
Cells were pelleted, washed with PBS, and resuspended in 200 ml of fluorescein isothiocyanate (FITC)-annexin V (1 mM/ml). After 15 min at room temperature, cells were washed with PBS and resuspended in 100 ml of fluorescence-activated cell-sorting buffer (PBS, 1% BSA, and 0.1% sodium azide) containing 7-ADD (20 mg/100 ml). Cells were incubated for 15 min at 41C in the dark. Analysis was performed using the FACScan flow cytometer (Beckman Coulter, Inc., Hialeah, FL, USA), and results were analysed with CelloQuest software (Becton Dickinson Immunocytometry Systmes, San Jose, CA, USA).
Antibodies
Polyclonal anti-phospho-P13K, anti-Bc1-X L , anti-caspase-3, and anti-caspase-9 antibodies were purchased from Santa Cruz (Santa Cruz, CA, USA), anti-DR5 and anti-DcR2 Laemmli (1970) using a Hoefer gel apparatus.
Immunoblot analysis
Proteins were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose membrane. The nitrocellulose membrane was blocked with 5% nonfat dry milk in PBSTween-20 (0.1%, v/v) at 41C overnight. The membrane was incubated with primary antibody (diluted according to the manufacturer's instructions) for 2 h. Horseradish peroxidaseconjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive protein was visualized by the chemiluminescence protocol (ECL, Amersham, Arlington Heights IL, USA). Quantitation of X-ray film was carried out by scanning densitometer (Personal Densitometer, Molecular Dynamics, Sunnyvale, CA, USA) using area integration.
In vitro enzyme assays
For in vitro PP1 phosphatase assays, 10 ml of active PP1a proteins (1 U/ml; Upstate Biotechnology) were incubated with 3 ml of active Akt (0.5 mg; Upstate Biotechnology) for 30 min at 301C in 50 ml of buffer (20 mM Tris-HC1, pH 7.5, 5 mM MgCl 2 , 100 mM ATP, 150 mM KC1, 5 mM b-glycerolphosphate, 0.1 mM sodium orthovanadate, 2 mM DTT).The reaction tubes contained either 1 mM amiloride or the same volume of DMSO.
The reaction was stopped by adding 2 Â SDS sample buffer and heating at 1001C for 5 min. Thereafter, the sample was subjected to SDS-PAGE and the phosphorylation of Akt was analysed by anti-phospho Akt antibody (Cell Signaling). For in vitro PDK-1 kinase assays, DU-145 cells were transiently transfected with PDK-1 constructs (pcDNA3myc-PDK-1; 2 mg of DNA/dish) using Lipofectamine Plus Reagent (Invitrogen, Carlsbad, CA, USA). At 1 day after transfection, cells were lysed with 500 ml of buffer A (20 mM Tris-HCl, pH 7.5, 1% Trition X-100, 0.5% deoxycholate, 5 mM EGTA, 150 mM NaCl, 10 mM NaF, 1 mM DTT, 1 mM sodium orthovanadate, 1 mM PMSF, and protein inhibitor cocktail solution (Sigma)). An aliquot of each lysate was immunoblotted to verify overexpression of PDK-1 constructs. Another aliquot was immunoprecipitated by incubation with mouse anti-myc antibody (9E10; Roche, Indianapolis, IN, USA) and protein G-Plus agarose (Gibco BRL) for 2 h at 41C. Immune complexes were washed twice with buffer B (150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 5 mM EGTA, 0.5 mM DTT, 1 mM Na 3 VO 4 , and 1 mM PMSF) at 41C and then incubated with 2 mg of purified inactive Akt protein (Upstate Biotechnology) in a volume of 50 ml of a kinase buffer (100 mM ATP, 20 mM Tris-HCl (pH 7.5), 20 mM MgC1, 0.1 mM EDTA) for 30 min at 301C. Thereafter, the sample was subjected to SDS-PAGE and the phosphorylation of Akt was analysed by rabbit antiphospho-Akt antibody (Cell Signaling).
For in vitro casein kinase 2 (CK2) kinase assays, 12.5 ml of active PTEN proteins (0.5 mg; Upstate) were incubated with 5 ml of active CK2 (0.5 mg; Upstate) for 30 min at 301C in 40 ml of kinase buffer (20 mM Tris-HC1, pH 7.5 5 mM MgCl 2 , 200 mm ATP, 150 mM KCI, 5 mM b-glycerolphosphate, 0.1 mM Na 3 VO 4 , 2 mM DTT). The reaction was stopped by adding 2 Â SDS sample buffer and heating at 1001C for 5 min. Thereafter, the sample was subjected to SDS-PAGE and the phosphorylation of PTEN was analysed by anti-phospho PTEN antibody (Cell Signaling).
Abbreviations DcR1, decoy receptor 1; DcR2, decoy receptor 2; DR4, death receptor 4; DR5, death receptor 5; DTT, dithiothreitol; FADD, Fas-associated death domain; FasL, Fas ligand; FLICE, Fas-associated death domain-like interleukin-1b-converting enzyme; FLIP, FLICE inhibitory protein; IAP, inhibitor of apoptosis; PAGE, polyacrylamide gel electrophoresis; PARP, poly (ADP-ribose) polymerase; PBS, phosphatebuffered saline; PDK-1, phosphoinositide-dependent kinase-1; PI3K, phosphatidylinositol 3-kinase; PP1, protein phosphatase 1; PTEN, phosphatase and tensin homolog deleted on chromosome 10; SDS, sodium dodecy1 sulfate; TNF, tumor necrosis factor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; DIDS, 4,4 0 -diisothiocyanatostilbene-2,2 0 -disulfonic acid; amiloride, 3,5-diamino-6-chloro-N-(diaminomethylene)pyrazinecarboximide.
